ASSET program concludes five-year innovation effort on precision medicine, diabetes screening

The five-year ASSET innovation program, coordinated by Diamyd Medical, has officially concluded. The program's work culminated in a final conference held in Stockholm, Sweden, on September 23, 2026, hosted by the Leading Health Care Foundation.

The conference, titled "Precision Medicine and the Future of Screening," brought together healthcare professionals and researchers. Discussions centered on the potential of artificial intelligence and data-driven approaches for the earlier detection of type-1 diabetes. The event also addressed regulatory and practical considerations for implementing a precision health approach within the Swedish healthcare system.

The ASSET initiative aimed to explore new strategies for diagnosing and treating type-1 diabetes. Through collaborative scientific efforts, the program sought to establish foundations for more personalized and effective care pathways. The project involved multiple European research institutions and healthcare stakeholders.

Diamyd Medical continues its focus on type-1 diabetes research and development. The knowledge and experiences gained during the ASSET program are expected to inform future projects. The company remains committed to advancing precision medicine in the field of diabetes.